Higher dose rate Gamma Knife radiosurgery may provide earlier and longer-lasting pain relief for patients with trigeminal neuralgia

John Y. K. Lee, MD, MSCE,1 Sukhmeet Sandhu, BA,1 Denise Miller, BSN,1 Timothy Solberg, PhD,2 Jay F. Dorsey, MD, PhD,2 and Michelle Alonso-Basanta, MD, PhD2

Departments of 1Neurosurgery and 2Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania

OBJECT  Gamma Knife radiosurgery (GKRS) utilizes cobalt-60 as its radiation source, and thus dose rate varies as the fixed source decays over its half-life of approximately 5.26 years. This natural decay results in increasing treatment times when delivering the same cumulative dose. It is also possible, however, that the biological effective dose may change based on this dose rate even if the total dose is kept constant. Because patients are generally treated in a uniform manner, radiosurgery for trigeminal neuralgia (TN) represents a clinical model whereby biological efficacy can be tested. The authors hypothesized that higher dose rates would result in earlier and more complete pain relief but only if measured with a sensitive pain assessment tool.

METHODS  One hundred thirty-three patients were treated with the Gamma Knife Model 4C unit at a single center by a single neurosurgeon during a single cobalt life cycle from January 2006 to May 2012. All patients were treated with 80 Gy with a single 4-mm isocenter without blocking. Using an output factor of 0.87, dose rates ranged from 1.28 to 2.95 Gy/min. The Brief Pain Inventory (BPI)-Facial was administered before the procedure and at the first follow-up office visit 1 month from the procedure (mean 1.3 months). Phone calls were made to evaluate patients after their procedures as part of a retrospective study. Univariate and multivariate linear regression was performed on several independent variables, including sex, age in deciles, diagnosis, follow-up duration, prior surgery, and dose rate.

RESULTS  In the short-term analysis (mean 1.3 months), patients’ self-reported pain intensity at its worst was significantly correlated with dose rate on multivariate analysis (p = 0.028). Similarly, patients’ self-reported interference with activities of daily living was closely correlated with dose rate on multivariate analysis (p = 0.067). A 1 Gy/min decrease in dose rate resulted in a 17% decrease in pain intensity at its worst and a 22% decrease in pain interference with activities of daily living. In longer-term follow-up (mean 1.9 years), GKRS with higher dose rates (> 2.0 Gy/min; p = 0.007) and older age in deciles (p = 0.012) were associated with a lower likelihood of recurrence of pain.

DISCUSSION  Prior studies investigating the role of dose rate in Gamma Knife radiosurgical ablation for TN have not used validated outcome tools to measure pain preoperatively. Consequently, differences in pain outcomes have been difficult to measure. By administering pain scales both preoperatively and postoperatively, the authors have identified statistically significant differences in pain intensity and pain interference with activities of daily living when comparing higher versus lower dose rates. Radiosurgery with a higher dose rate results in more pain relief at the early follow-up evaluation, and it may result in a lower recurrence rate at later follow-up.


KEY WORDS  trigeminal neuralgia; Gamma Knife radiosurgery; dose rate; Brief Pain Inventory-Facial; stereotactic radiosurgery; pain

Abbreviations

AED = antiepileptic drug; BNI = Barrow Neurological Institute; BPI = Brief Pain Inventory; GKRS = Gamma Knife radiosurgery; TN = trigeminal neuralgia; TN1 = TN Type 1; TN2 = Type 2.

Submitted  August 30, 2014.  Accepted  December 30, 2014.

Include when citing  Published online August 7, 2015; DOI: 10.3171/2014.12/JNS142013.

Disclosure  The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

©AANS, 2015
Prior studies of GKRS for TN have shown differences in outcomes associated with total dose delivered to the trigeminal nerve, but studies have not identified any significant differences as a result of the rate at which the dose was delivered. The outcome measures used in those studies have been particularly crude, and no study has measured pain prior to GKRS intervention. Zakrezewska et al.’s review suggests that only a fraction of outcome studies in TN have actually measured pain prior to intervention. Most studies have assumed that pain is “severe” and has affected quality of life, without attempting to measure either of these factors. The senior author (J.Y.K.L.) published the validation study of the Brief Pain Inventory (BPI)-Facial outcome tool in 2010. This outcome tool can be used to measure pain before and after GKRS to measure change in pain in a quantitative manner, thus providing greater insight to the effects of various patient- and treatment-related parameters. We hypothesized that administration of this tool prior to GKRS may provide a more sensitive test of efficacy, allowing us to study the effect of dose rate in a more systematic manner.

Methods

Study Population

This study was a retrospective review of all patients treated by a single neurosurgeon (J.Y.K.L.) at a single hospital (Pennsylvania Hospital at the University of Pennsylvania) from 2006 to 2012, approved by the University of Pennsylvania Institutional Review Board. All patients completed the BPI-Facial outcome tool at the first clinic visit as well as at subsequent clinic visits, including postoperatively after GKRS. Paper forms were completed by the patients at their own pace without physician supervision. Also, patients were not given their prior BPI-Facial forms to reference when they completed the postoperative BPI-Facial. Hence, all results represent blinded, uninstrumented, patient-oriented outcomes. These forms were stored in the paper chart until 2012, at which time data were collected and entered into a computerized relational database (Access, Microsoft Corp.). Data were analyzed using STATA statistical software (version 10, StataCorp LP).

Gamma Knife Treatment Parameters

The University of Pennsylvania Gamma Knife unit at Pennsylvania Hospital (Model 4C, Elekta AB) was installed in November 2005 and patients with TN were treated from January 2006 until May 2012. After May 2012, the 4C unit was upgraded to a Leksell Gamma Knife Perfexion unit. All patients were treated by the senior author (J.Y.K.L.) and almost all patients were prescribed 80 Gy to the 100% maximum dose with a 4-mm collimator. No blocks were used in any patient. An output factor of 0.87 was used throughout the period. All patients were advised to remain on their same dose of medications until their first postoperative visit, at which time they were advised as to how to taper their medications.

Data Collection

Patient data were collected before GKRS, at the patients’ first postprocedure visit scheduled approximately 1 month after the GKRS procedure, and during the telephone questionnaire in 2012. Details of the data analysis have been presented elsewhere (Lee et al. 2010), but in brief, postoperative raw scores were subtracted from preoperative raw scores, divided by the preoperative raw score, and multiplied by 100 to obtain a percentage change. The 7 interference items of the general activities of daily living were averaged together, and the 7 interference items of the facial activities of daily living were averaged together.

Statistical Analysis

Short-term analysis of the 1-month postprocedure data was performed using STATA 10. The BPI-Facial provides quantitative comparisons between the preoperative baseline score and the postoperative score at 1 month. The percentage change in the preoperative and postoperative score was used as the outcome variable. Linear regression was used to compare predictor variables. Dose rate was tested as a continuous variable, and sex, age in deciles, follow-up duration, diagnosis (Burchiel TN Type 1 [TN1] vs Burchiel TN2, and any TN diagnosis versus “other diagnosis”), and prior surgery for TN (yes or no) were tested as univariate variables. Variables with p values less than 0.3 were entered into the multivariate linear regression model.

For longer-term outcomes, telephone questionnaires were initiated in 2012, and they followed a prescribed routine, including administration of the BPI-Facial. Patients who could not be contacted were considered censored at their last available follow-up evaluation, which was usually their 1-month posttreatment office visit. Any pain recurrence was defined as “any pain” regardless of whether the patient described it as “sharp, shooting” or “constant, burning.” In addition, a medication list was obtained from the patient, but no attempt was made to discern the cause for taking medications, such as radiculopathy pain versus TN pain. Cox regression was used to test predictor variables. Univariate predictors included the following: dose rate (high vs low), sex, age in deciles, follow-up duration, diagnosis (Burchiel TN1 vs Burchiel TN2, and any TN diagnosis versus “other diagnosis”), and prior surgery for TN (yes or no). Variables with a p value less than 0.3 were entered into the multivariate model.

Results

A total of 133 patients were treated during the time period (Table 1). Of these patients, 57% were female, and the mean age was 68 years (range 35–95 years). Right-sided facial pain was observed in 55%. Eighty-four percent of the total study population was treated for a diagnosis of multiple sclerosis–related TN. The remaining 6% of patients were treated for a diagnosis of atypical facial pain or other diagnosis. Almost one-quarter of the patients (24%) had previously been treated with a neurosurgical procedure for their TN.

Ninety-seven percent of patients were prescribed the same dose, 80 Gy to the 100% maximum. Only 4 patients were treated with a dose lower than 80 Gy, and these were all retreatments (50, 60, 70, and 75 Gy each). The mean
GKRS dose rate was 2.04 Gy/min, and the range varied from 1.28 to 2.95 Gy/min.

**Short-Term Results**

Patients were evaluated in the office an average of 1.3 months after the GKRS procedure. Patients were not asked to taper medications until this early posttreatment visit, and thus most patients remained on the same medications at the time of data collection. Even at this early time point, the majority of patients reported improvement after their GKRS procedure. Fifty-nine percent of patients rated themselves as "very much improved" or "much improved" using a 7-point Global Impression of Change ranging from "very much improved" to "very much worse." Statistically, patients as a group demonstrated significant improvement in all dimensions of pain as measured by the BPI-Facial (Table 2). For example, mean preoperative pain, at its worst, was 7.9, versus 4.4 at 1 month after GKRS (Fig. 1). Similarly, the mean preoperative BPI-Facial score for the averaged interference with general activities items was 6.7 before GKRS and 2.6 at 1 month afterward (Table 2).

Univariate and multivariate linear regression was used to build a model to predict the percentage change in pain intensity (worst and average), interference with general activities of daily living, and interference with facial-specific activities of daily living (Table 3). At 1-month follow-up, for pain at its worst, the strongest predictor of percentage pain relief was dose rate (p = 0.028). The coefficient was 17%, and hence a 1 Gy/min decrease in dose rate resulted in a 17% less change in pain intensity at its worst between the preoperative and postoperative score (Fig. 2). Similarly, at 1-month follow-up, for interference of general activities of daily living, the strongest predictor of percentage pain relief was dose rate (p = 0.067). The coefficient was 22%, and hence a 1 Gy/min decrease in dose rate resulted in a 22% less change in the averaged interference of general activities of daily living between the preoperative and postoperative score. At the earliest time point (mean 1.3 months after GKRS), using multivariate analysis, no variable was a significant predictor of pain intensity on average or interference of facial-specific activities of daily living.

**Long-Term Follow-Up**

To study long-term outcomes, patients were called an average of 1.9 years after their GKRS procedure (range 0.2–6.7 years). Ninety-nine of the total 133 patients consented to participation in the long-term follow-up study and/or were able to be contacted via telephone. The remaining 34 patients were considered censored at their 1-month follow-up visit.

Forty-one patients reported recurrence of "any facial pain" at some time point after their procedure, resulting in a crude pain recurrence rate of 31% (41/133). Kaplan-Meier survival methods were used to calculate “time to event,” in this case “time to any facial pain recurrence.” The median duration of freedom from pain recurrence was 4.1 years (Fig. 3).

Cox regression was used to calculate univariate and multivariate predictors of pain recurrence. In multivariate analysis, 2 variables were statistically significant predictors of pain recurrence: age in deciles (p = 0.012), and dose rate (high vs low, p = 0.007; Table 4). Figure 4 demonstrates the percentage of failure according to each age decade. Younger patients were more likely to experience pain recurrence. Also, because the median dose rate was calculated to be 2.0 Gy/min, patients were grouped into high dose rate (> 2.0 Gy/min) and low dose rate (< 2.0 Gy/min).

---

**TABLE 1. Patient characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>133</td>
</tr>
<tr>
<td>Female (%)</td>
<td>57</td>
</tr>
<tr>
<td>Rt-sided pain (%)</td>
<td>55</td>
</tr>
<tr>
<td>Follow-up duration in mos (range)</td>
<td>1.3 (0–7.9)</td>
</tr>
<tr>
<td>Diagnosis (%)</td>
<td></td>
</tr>
<tr>
<td>Burchiel TN1</td>
<td>66</td>
</tr>
<tr>
<td>Burchiel TN2</td>
<td>18</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>10</td>
</tr>
<tr>
<td>Atypical facial pain &amp; other</td>
<td>6</td>
</tr>
<tr>
<td>Age in deciles (%)</td>
<td></td>
</tr>
<tr>
<td>&lt;50 yrs</td>
<td>10</td>
</tr>
<tr>
<td>50–60 yrs</td>
<td>16</td>
</tr>
<tr>
<td>60–70 yrs</td>
<td>25</td>
</tr>
<tr>
<td>70–80 yrs</td>
<td>33</td>
</tr>
<tr>
<td>&gt;80 yrs</td>
<td>17</td>
</tr>
<tr>
<td>Mean age in yrs (range)</td>
<td>68 (35–95)</td>
</tr>
<tr>
<td>Mean GKRS dose rate in Gy/min (range)</td>
<td>2.04 (1.28–2.95)</td>
</tr>
<tr>
<td>Maximum dose in Gy</td>
<td>median 80 (50–80)</td>
</tr>
<tr>
<td>Prior procedures (%)</td>
<td></td>
</tr>
<tr>
<td>Microvascular decompression</td>
<td>5</td>
</tr>
<tr>
<td>Percutaneous rhizotomy</td>
<td>12</td>
</tr>
<tr>
<td>GKRS</td>
<td>7</td>
</tr>
</tbody>
</table>

---

**TABLE 2. Preoperative and postoperative BPI-Facial scores**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-Procedure Score</th>
<th>1-month Score</th>
<th>p Value</th>
<th>Long-Term Score</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain at its worst</td>
<td>7.9</td>
<td>4.4</td>
<td>0.0001</td>
<td>2.4</td>
<td>0.0001</td>
</tr>
<tr>
<td>Pain on average</td>
<td>6.0</td>
<td>3.0</td>
<td>0.0001</td>
<td>1.4</td>
<td>0.0001</td>
</tr>
<tr>
<td>BPI-General interference items (mean)</td>
<td>6.7</td>
<td>2.6</td>
<td>0.0001</td>
<td>1.1</td>
<td>0.0001</td>
</tr>
<tr>
<td>BPI-Facial interference items (mean)</td>
<td>5.6</td>
<td>2.3</td>
<td>0.0001</td>
<td>1.3</td>
<td>0.0001</td>
</tr>
<tr>
<td>% of patients on AED pain medications</td>
<td>90</td>
<td>85</td>
<td></td>
<td>43</td>
<td></td>
</tr>
</tbody>
</table>
Patients treated with a higher dose rate were more likely to be pain-free at the last follow-up time period as compared with patients treated with a lower dose rate (Fig. 5).

As a check of internal consistency of the long-term outcomes, we compared the BPI-Facial scores for the patients who had pain recurrence as well as those who did not (Table 5). Patients who described themselves as having had a recurrence reported 59% change in pain at its worst between their preoperative and postoperative score. In contrast, patients who described themselves as not having had a recurrence, reported 78% change in pain at its worst between their preoperative and postoperative score (p = 0.054). Interestingly, even though patients reported themselves as having recurrent pain, they still demonstrated improvement as compared with their baseline scores. This may be related to the fact that they were not shown their original pain scores when they were asked over the telephone what their pain level was at present.

As another level of internal consistency of long-term outcomes, we compared the likelihood of taking antiepileptic drugs (AEDs) before and after GKRS. Every patient had tried AEDs prior to GKRS. At the time of the procedure, 90% of patients were actively taking AEDs. At last follow-up, 43% of all patients were taking AEDs. However, patients who were considered to have had a recurrence of pain were almost 3 times more likely to be taking AEDs as compared with patients who did not have pain recurrence (63% vs 26%, respectively; p < 0.05, Fisher’s exact test).

Of note, 10% of patients reported new numbness or change in the distribution of preexisting numbness at the last follow-up evaluation. Figure 6 demonstrates the time to numbness for patients who had a recurrence of pain. This was not a statistically significant predictor of outcome at the last follow-up evaluation.

**Discussion**

Gamma Knife radiosurgery is one of several treatment modalities for patients with idiopathic TN. Approximately 75% to 80% of patients experience pain relief, and the median pain-free period after the procedure is approximately 3 to 5 years. Predictors of pain relief in patients undergoing radiosurgery have included patient factors such as young age, absence of prior procedures, shorter pain duration before the procedure, and development of facial numbness. Some features of the GKRS procedure itself have been identified as predictors of pain relief, such as higher total dose and greater total volume of nerve irradiated. Only 2 prior studies have investigated the role of dose rate in TN outcomes, and they found no correlation. We hypothesized that one possible limitation of these prior studies was the lack of a sensitive measurement tool for TN pain, and thus subtle differences between patients and within patients may be lost by

---

**TABLE 3. Predictors of short-term pain relief based on percentage change**

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Pain Intensity Worst</th>
<th>Pain Intensity Average</th>
<th>BPI-General Interference Items</th>
<th>BPI-Facial Interference Items</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose rate</td>
<td>0.076</td>
<td>0.5212</td>
<td>0.053</td>
<td>0.3261</td>
</tr>
<tr>
<td>Sex</td>
<td>0.8105</td>
<td>0.666</td>
<td>0.4104</td>
<td>0.1091</td>
</tr>
<tr>
<td>Age in deciles</td>
<td>0.9657</td>
<td>0.9602</td>
<td>0.8248</td>
<td>0.8755</td>
</tr>
<tr>
<td>Follow-up duration (mos)</td>
<td>0.7489</td>
<td>0.8359</td>
<td>0.2714</td>
<td>0.2861</td>
</tr>
<tr>
<td>Diagnosis (TN1 vs TN2)</td>
<td>0.832</td>
<td>0.7698</td>
<td>0.8527</td>
<td>0.5876</td>
</tr>
<tr>
<td>Diagnosis (Any TN vs other)</td>
<td>0.1099</td>
<td>0.2355</td>
<td>0.5498</td>
<td>0.3551</td>
</tr>
<tr>
<td>Prior surgery for TN</td>
<td>0.2302</td>
<td>0.1082</td>
<td>0.7293</td>
<td>0.5732</td>
</tr>
<tr>
<td>Maximum dose</td>
<td>0.2915</td>
<td>0.4106</td>
<td>0.4167</td>
<td>0.5107</td>
</tr>
</tbody>
</table>

Multi. = multivariate analysis; Uni. = univariate analysis.

*p values given in table are p values.
Higher dose rate Gamma Knife radiosurgery and TN outcomes

not measuring pain before and after the procedure. In this context, we hypothesized that the BPI-Facial (Appendix) may provide insight by providing a numeric measure of pain intensity and pain interference with activities of daily living.11

Traditional studies in TN have used the Barrow Neurological Institute (BNI) pain outcome scale. The BNI is a composite scale with psychometric properties that has not been validated. The scale classifies pain into subjective categories: none, occasional, some, severe. In addition, this composite scale combines use of pain medications into its scale and grades medication use into 3 categories: no medications, and some medications with or without adequate pain relief. Although this scale allows for 12 discrete permutations of outcomes, only 5 or sometimes 6 of the permutations are used for grading. In addition, changes from baseline are not used with the BNI scale. Hence, the senior author did not consider this scale to be appropriate for short-term analysis. Another alternative method of measuring pain outcomes used in the TN literature is survival analysis, which is a method of studying the “time to event.” Because 1-month follow-up was not considered to be long enough for the event of interest (pain recurrence), an alternative and actually more traditional method of pain outcome analysis was used. Pain was measured before and after intervention using a multidimensional scale, the BPI-Facial.

In our study we scored pain on a scale of 0–10 before and after intervention. Patients rated their facial pain at its worst as 7.9 and then 4.4 at their 1-month postprocedure visit (Table 2). Thus, because the BPI-Facial provides a numerical outcome measure, we then performed a linear regression to predict percentage change. This powerful technique demonstrated that dose rate was the most significant predictor of pain relief (p = 0.028) on multivariate regression (Table 3). This analysis was repeated for pain interference with activities of daily living, and dose rate was once again the most powerful predictor of pain relief (p = 0.067). Thus, patients treated with a dose rate > 2 Gy/min experienced more dramatic pain relief at their 1-month follow-up visit.

Prior studies have examined the effect of dose rate on TN outcomes. Arai et al. from the University of Pittsburgh studied 165 patients treated with a maximum dose of 80 Gy. The primary outcome tool was the BNI pain scale. The investigators divided the 165 patients into a high-dose group and a low-dose group in a dichotomous fashion. No attempt was made to measure pain before the GKRS procedure. At the last follow-up evaluation, the patient was assigned a BNI scale from 1–6, and patients with scores of 1, 2, 3A, and 3B were considered to have successful outcome. Seventy-one percent of the low dose rate group and 78% of the high dose rate group achieved successful outcome at last follow-up (p = 0.547). The authors concluded that there was no statistically significant difference between the low dose rate and high dose rate groups. In another study from Wake Forest, Balamucki et al. studied 256 patients and classified outcome according to their own scale: excellent, good, fair, and poor. Success was defined as any category except poor, in which poor was defined as “less than 50% pain relief with or without medications.” Again, pain was not measured before intervention. Because the treating physicians used varying doses throughout the treatment period, the investigators attempted to control for the effect of total dose, and based on logistic regression, they concluded that there was no significant correlation between pain relief and dose rate. In addition, using Cox regression, no significant difference was identified in time to pain recurrence based on dose rate. We suspect that one of the reasons these 2 studies have been unable to correlate dose rate with pain outcomes is their use of crude outcome tools in the study of pain.

### Table 4. Predictors of long-term pain relief*

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Univariate</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose rate (high/low)</td>
<td>0.0008</td>
<td>0.007</td>
</tr>
<tr>
<td>Sex</td>
<td>0.1756</td>
<td>0.083</td>
</tr>
<tr>
<td>Age in deciles</td>
<td>0.061</td>
<td>0.012</td>
</tr>
<tr>
<td>Follow-up time (high/low)</td>
<td>0.999</td>
<td></td>
</tr>
<tr>
<td>Diagnosis (TN1 vs TN2)</td>
<td>0.1334</td>
<td>0.215</td>
</tr>
<tr>
<td>Diagnosis (any TN vs other)</td>
<td>0.9953</td>
<td></td>
</tr>
<tr>
<td>Prior surgery for TN</td>
<td>0.2563</td>
<td></td>
</tr>
<tr>
<td>Any numbness</td>
<td>0.1416</td>
<td>0.114</td>
</tr>
</tbody>
</table>

* Cox regression was used to calculate p values.

**FIG. 3.** Kaplan-Meier curve estimating the time to any pain recurrence after GKRS.

**FIG. 4.** Bar graph demonstrating the percentage of patients who experienced pain recurrence, according to age deciles (fourth through ninth decade of life).
To improve upon the BNI pain grading scale, we chose to create and use the BPI-Facial. This validated outcome tool uses 4 questions targeting pain intensity, 7 questions targeting pain interference with general activities of daily living, and 7 questions targeting pain interference with facial-specific activities of daily living. The BPI-Facial was administered before and after intervention as well as at the long-term telephone follow-up evaluation. It provides numerical outcome measures that allows for quantitative analysis. In addition, pain scale reports are provided by the patient and not by the treating physician or investigator, thereby limiting reporting bias. We suspect that the lack of clinically significant differences between the high dose rate and low dose rate in the studies by Arai et al. and Balamucci et al. reflects the insensitive outcome tool chosen by the investigators.

The BPI-Facial provides quantitative outcome measures, but to measure durability of clinical outcomes, we chose to employ the standard technique of actuarial Kaplan-Meier analysis using Cox regression. This statistical technique requires a dichotomous outcome (better or not better). A stringent criterion of “any TN pain” versus “none” was chosen for the dichotomous outcome. No account was made as to whether the patient was on medications or not, except to record name, dose and frequency. Using this technique, we performed multivariate Cox regression, and we confirmed that dose rate was the most significant predictor of freedom from pain recurrence.

In our study we could not confirm several published findings that have been shown to be predictors of pain relief. For example, several authors have correlated numbness with pain relief. We did not find an association of pain response with development of new numbness or hypesthesia. In addition, we found that younger age, not older age, was associated with recurrence of pain, but this may reflect lack of long term follow-up, and we will have to continue to study longer term outcomes to confirm this findings. In addition, we did not review location of the GKRS isocenter as a predictor of outcome. Despite these limitations and negative findings, we believe that the data we present strongly support the hypothesis that radiosurgical dose rate predicts outcome in patients with TN.

It is known that equivalent doses of absorbed radiation do not necessarily produce equivalent biological effects. The biological effect, or so-called relative biological effectiveness, of a prescribed dose of radiation depends on the following set of factors: 1) dose, 2) fractionation, 3) biological system, 4) quality of radiation (i.e., linear energy transfer), and 5) dose rate. It is provocative to speculate that the dose rate of cobalt-60 gamma radiation may potentially have an impact on pain outcomes in patients with TN. However, previous studies comparing the dose rate effect of cobalt-60 gamma irradiation of human lymphocytes failed to demonstrate an appreciable difference in the level of radiation effect as measured by chromosomal aberrations when human lymphocytes were exposed to the equivalent dose of radiation (approximately 2 or 4 Gy) and delivered over a 2- or 10-minute time period.

To our knowledge, our study is the first study to demonstrate an actual effect of dose rate on pain control rates in the treatment of TN and potentially warrant further exploration. However, this study raises intriguing considerations.

<table>
<thead>
<tr>
<th>Variable</th>
<th>No Recurrence</th>
<th>Recurrence</th>
<th>p Value</th>
<th>Absolute Change</th>
<th>% Change</th>
<th>Absolute Change</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain intensity-worst</td>
<td>3.6</td>
<td>1.5</td>
<td>0.0028</td>
<td>78</td>
<td>59</td>
<td>0.054</td>
<td>0.054</td>
</tr>
<tr>
<td>Pain intensity-average</td>
<td>1.9</td>
<td>0.9</td>
<td>0.044</td>
<td>83</td>
<td>71</td>
<td>0.1849</td>
<td>0.1849</td>
</tr>
<tr>
<td>BPI-General interference items (average)</td>
<td>1.4</td>
<td>0.6</td>
<td>0.065</td>
<td>86</td>
<td>76</td>
<td>0.237</td>
<td></td>
</tr>
<tr>
<td>BPI-Facial interference items (average)</td>
<td>1.8</td>
<td>0.9</td>
<td>0.055</td>
<td>85</td>
<td>71</td>
<td>0.16</td>
<td></td>
</tr>
<tr>
<td>% of patients on AED pain medications*</td>
<td>26</td>
<td>63</td>
<td>0.0005</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Fisher’s exact test.
for treatment of patients with TN. In this study all patients were treated with 80 Gy to the maximum. If the Gamma Knife dose rate has diminished due to cobalt source decay, should the patient be treated with a higher dose such as 85 Gy or 90 Gy to counteract the potentially diminishing biological effect associated with lower dose rate? Because this study is retrospective and as such is only hypothesis-generating, we believe that changes to clinical practice should only be performed after this finding is validated in a prospective manner.

This study has limitations, as it is a retrospective study with nonblinded, telephone questionnaire follow-up. Indeed, telephone questionnaires can be difficult to administer in patients of advanced age and poor hearing, but we believe our telephone interviewers did everything possible to keep the measures objective. This study was not prospectively designed, although the BPI-Facial was administered in a prospective manner. As such, we do encourage other investigators to use the BPI-Facial as a simple and easy way to measure pain in patients with TN. The BPI-Facial is scored by the patient, and thus this limits bias by the treating physician, but obviously this study was not blinded and no independent observer was used to measure outcomes. Because this study was not a controlled study, there is no way to measure the placebo effect in this paper. However, future studies can use the BPI-Facial to measure, in a quantitative manner, the placebo effect of different procedures in patients with TN. Despite these limitations, we find these results to be hypothesis-generating and worthy of discussion.

**Conclusions**

A higher dose rate GKRS for TN appears to result in greater magnitude of pain relief at an early follow-up evaluation (1 month). In addition, higher dose rate appears to result in lower rate of recurrence. These results have been generated through use of a validated pain outcome tool that was administered before and after intervention, but these results need to be validated by larger, multiinstitutional studies.

**Appendix**

The Brief Pain Inventory—Facial

Circle the ONE number that describes how, during the past week, pain has interfered with your:

1. General activity
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

2. Mood
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

3. Walking ability
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

4. Normal work (includes both work outside the home and housework)
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

5. Relations with other people
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

6. Sleep
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

7. Enjoyment of life
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

8. Eating a meal
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

9. Touching your face (including grooming)
   - 0 1 2 3 4 5 6 7 8 9 10
   - Does not interfere
   - Completely interferes

10. Brushing or flossing your teeth
    - 0 1 2 3 4 5 6 7 8 9 10
    - Does not interfere
    - Completely interferes

11. Smiling or laughing
    - 0 1 2 3 4 5 6 7 8 9 10
    - Does not interfere
    - Completely interferes

12. Talking
    - 0 1 2 3 4 5 6 7 8 9 10
    - Does not interfere
    - Completely interferes

13. Opening your mouth widely
    - 0 1 2 3 4 5 6 7 8 9 10
    - Does not interfere
    - Completely interferes

14. Eating hard foods like apples
    - 0 1 2 3 4 5 6 7 8 9 10
    - Does not interfere
    - Completely interferes
Circle the ONE number that describes your pain in the last week.

No pain

Circle the ONE number that describes your pain at its WORST in the last week.

0 1 2 3 4 5 6 7 8 9 10

Pain as bad as you can imagine

Circle the ONE number that describes your pain at its LEAST in the last week.

0 1 2 3 4 5 6 7 8 9 10

Pain as bad as you can imagine

Circle the ONE number that describes your pain at its AVERAGE in the last week.

0 1 2 3 4 5 6 7 8 9 10

Pain as bad as you can imagine

Circle the ONE number that describes your pain RIGHT NOW.

0 1 2 3 4 5 6 7 8 9 10

Pain as bad as you can imagine


References


Author Contributions


Correspondence

John Y. K. Lee, Department of Neurosurgery, University of Pennsylvania, 235 S. Eighth St., Philadelphia, PA 19106. email: leejohn@uphs.upenn.edu.